Teva Pharmaceutical Industries (TEVA) Operating Margin (2016 - 2025)
Historic Operating Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 6.37%.
- Teva Pharmaceutical Industries' Operating Margin rose 70500.0% to 6.37% in Q4 2025 from the same period last year, while for Dec 2025 it was 12.49%, marking a year-over-year increase of 143200.0%. This contributed to the annual value of 12.5% for FY2025, which is 143300.0% up from last year.
- Per Teva Pharmaceutical Industries' latest filing, its Operating Margin stood at 6.37% for Q4 2025, which was up 70500.0% from 19.69% recorded in Q3 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Operating Margin ranged from a high of 19.69% in Q3 2025 and a low of 25.54% during Q2 2022
- Over the past 5 years, Teva Pharmaceutical Industries' median Operating Margin value was 4.14% (recorded in 2021), while the average stood at 1.88%.
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Operating Margin skyrocketed by 1251800bps in 2021, and later plummeted by -404300bps in 2022.
- Over the past 5 years, Teva Pharmaceutical Industries' Operating Margin (Quarter) stood at 1.9% in 2021, then crashed by -1372bps to 24.2% in 2022, then surged by 170bps to 16.96% in 2023, then crashed by -104bps to 0.69% in 2024, then surged by 1029bps to 6.37% in 2025.
- Its Operating Margin was 6.37% in Q4 2025, compared to 19.69% in Q3 2025 and 10.9% in Q2 2025.